OptiNose - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsOptiNose

OptiNose(OPTN)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Xhance	Fluticasone	2017-09-18	2024-2041	Chronic obstructive pulmonary disease , Asthma , Allergic rhinitis perennial , Bronchial spasm , Allergic conjunctivitis , Vasomotor rhinitis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

therapeutic equivalency

,

diabetes mellitus

,

type 1 diabetes mellitus

,

knee osteoarthritis

,

,

,

bronchiolitis obliterans syndrome

,

pharmacokinetics

,

graft vs host disease

,

medication adherence

,

pulmonary eosinophilia

,

,

myelodysplastic syndromes

,

myeloid leukemia acute

,

non-hodgkin lymphoma

,

multiple myeloma

,

,

precursor cell lymphoblastic leukemia-lymphoma

,

b-cell chronic lymphocytic leukemia

,

bcr-abl positive chronic myelogenous leukemia

,

hodgkin disease

,

plasma cell neoplasms

,

lymphoid leukemia

,

,

bronchogenic carcinoma

,

autistic disorder

,

autism spectrum disorder

,

pervasive child development disorders

,

altitude sickness

,

,

,

,

bronchiolitis obliterans

,

respiratory tract diseases

,

respiration disorders

,

allergic bronchopulmonary aspergillosis

,

,

,

,

bacterial pneumonia

,

gastrointestinal diseases

,

digestive system diseases

,

pulmonary emphysema

,

migraine disorders

,

respiratory insufficiency

,

deglutition disorders

,

,

pulmonary aspergillosis

,

,

viral pneumonia

,

,

,

cardiovascular diseases

,

colorectal neoplasms

,

nasopharyngeal neoplasms

,

,

allergic contact dermatitis

,

allergic fungal sinusitis

,

,

chronic obstructive pulmonary disease

,

,

obstructive lung diseases

,

,

allergic rhinitis

,

allergic rhinitis seasonal

,

respiratory aspiration

,

allergic rhinitis perennial

,

eosinophilic esophagitis

,

,

,

hypersensitivity

,

healthy volunteers/patients

,

,

,

atopic dermatitis

,

chronic disease

,

,

,

,

chronic bronchitis

,

,

allergic conjunctivitis

,

sleep apnea syndromes

,

respiratory sounds

,

,

obstructive sleep apnea

,

,

exercise-induced asthma

,

,

,

,

disease progression

,

,

respiratory tract infections

,

,

bronchial spasm

,

,

,

airway obstruction

,

,

ocular hypertension

,

,

open-angle glaucoma

,

dust mite allergy

,

,

,

depressive disorder

,

,

disorders of excessive somnolence

,

,

metabolic bone diseases

,

,

,

voice disorders

,

oral candidiasis

,

,

immune system diseases

,

bronchial diseases

,

respiratory hypersensitivity

,

,

respiratory signs and symptoms

,

,

adrenal insufficiency

,

exercise tolerance

,

,

cystic fibrosis

,

paranasal sinus diseases

,

,

tobacco use disorder

,

tobacco smoking

,

sleep wake disorders

,

bronchial hyperreactivity

,

nebulizers and vaporizers

,

,

,

,

nasal obstruction

,

,

,

acupuncture therapy

,

atrophic rhinitis

Fluticasone furoate

,

respiratory aspiration

,

,

,

,

chronic disease

,

colorectal neoplasms

,

nasopharyngeal neoplasms

Fluticasone propionate

allergic rhinitis

,

,

allergic rhinitis seasonal

,

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use